# filter[].description
Indicates the availability of the vaccine in the United States.

# filter[].value
One of: 'active', 'inactive', 'pending', 'never-active', 'non-US'

# filter[].description
If 'true', this is not a product that is not a vaccine.

# property[].description
Instructions on usage or other relevant notes.

# property[].description
Indicates the availability of the vaccine in the United States.

# property[].description
If 'true', this is not a product that is not a vaccine.

# property[].description
Indicates the last time this particular vaccine code was updated.

# concept[].designation[].value
diphtheria, tetanus toxoids and pertussis vaccine

# concept[].designation[].value
trivalent poliovirus vaccine, live, oral

# concept[].property[].valueString
This is the OPV used in the US from June 1963 through Dec 1999 and globally through April 2016

# concept[].designation[].value
measles, mumps and rubella virus vaccine

# concept[].designation[].value
hepatitis B vaccine, pediatric or pediatric/adolescent dosage

# concept[].property[].valueString
This code applies to any standard pediatric formulation of Hepatitis B vaccine. It should not be used for the 2-dose hepatitis B schedule for adolescents (11-15 year olds). Use code 43 for that vaccine.

# concept[].display
Td (adult), 2 Lf tetanus toxoid, preservative free, adsorbed

# concept[].designation[].value
tetanus and diphtheria toxoids, adsorbed, preservative free, for adult use (2 Lf of tetanus toxoid and 2 Lf of diphtheria toxoid)

# concept[].display
influenza, split (incl. purified surface antigen)

# concept[].designation[].value
influenza virus vaccine, split virus (incl. purified surface antigen)-retired CODE

# concept[].property[].valueString
This code is being retired. It will still be found in older immunization records. It included both preservative free and non-preservative free.

# concept[].designation[].value
Haemophilus influenzae type b vaccine, conjugate unspecified formulation

# concept[].designation[].value
rabies vaccine, for intramuscular injection RETIRED CODE

# concept[].property[].valueString
This CVX code has been retired. It is replace by CVX 175,  or CVX 176. It will continue to be found in historic records.

# concept[].designation[].value
diphtheria, tetanus toxoids and acellular pertussis vaccine

# concept[].designation[].value
DTP-Haemophilus influenzae type b conjugate vaccine

# concept[].designation[].value
Anthrax vaccine, adsorbed, pre-exposure and post-exposure prophylaxis

# concept[].designation[].value
diphtheria and tetanus toxoids, adsorbed for pediatric use

# concept[].property[].valueString
Retired effective 04/30/2023.  All vaccine NDCs retired.  No further vaccines expected for this formulation.

# concept[].display
Hep A, pediatric, unspecified formulation

# concept[].designation[].value
hepatitis A vaccine, pediatric dosage, unspecified formulation

# concept[].property[].valueString
Do NOT use this code.  If formulation is unknown, use CVX 85.  There is only one formulation of Hep A, peds.

# concept[].designation[].value
pneumococcal polysaccharide vaccine, 23 valent

# concept[].property[].valueString
This is the YF vaccine that has been available in the US for years. It is stabilized with sorbitol and gelatin.

# concept[].designation[].value
rabies vaccine, for intradermal injection

# concept[].designation[].value
typhoid vaccine, parenteral, other than acetone-killed, dried

# concept[].designation[].value
hepatitis B vaccine, adolescent/high risk infant dosage

# concept[].property[].valueString
As of August 27, 1998, Merck ceased distribution of their adolescent/high risk infant hepatitis B vaccine dosage. Code 42 should only be used to record historical records. For current administration of hepatitis B vaccine, pediatric/adolescent dosage, use code 08.

# concept[].property[].valueString
This code applies to any standard adult dose and schedule. Also use CVX 43 for the FDA approved Recombivax HB 2-dose hepatitis B schedule for adolescents (11-15 year olds) using the adult formulation.

# concept[].designation[].value
Hepatitis B vaccine (Hep B), high-dosage, dialysis or immunocompromised patient

# concept[].property[].valueString
This code is used record patient high dosage vaccine administration for dialysis or immunocompromised patients. For NDCs that are used for both regular vaccine and dialysis/IC high-dosage schedules (e.g. Engerix-B), are mapped to both CVX 43 and CVX 44. CVX code 44 should be utilized to record dialysis/IC dosing.

# concept[].designation[].value
hepatitis B vaccine, unspecified formulation

# concept[].property[].valueString
This CVX code allows reporting of a vaccination when formulation is unknown (for example, when recording a HepB vaccination when noted on a vaccination card)

# concept[].designation[].value
Haemophilus influenzae type b vaccine, PRP-D conjugate

# concept[].designation[].value
Haemophilus influenzae type b vaccine, HbOC conjugate

# concept[].designation[].value
Haemophilus influenzae type b vaccine, PRP-T conjugate

# concept[].designation[].value
Haemophilus influenzae type b vaccine, PRP-OMP conjugate

# concept[].designation[].value
DTaP-Haemophilus influenzae type b conjugate vaccine

# concept[].designation[].value
Haemophilus influenzae type b conjugate and Hepatitis B vaccine

# concept[].property[].valueString
This vaccine may still be in use until the existing lots expire on 8/19/16.

# concept[].display
typhoid, parenteral, AKD (U.S. military)

# concept[].designation[].value
typhoid vaccine, parenteral, acetone-killed, dried (U.S. military)

# concept[].property[].valueString
Applies to tetravalent product (e.g. DENGVAXIA)

# concept[].designation[].value
human papilloma virus vaccine, quadrivalent

# concept[].designation[].value
respiratory syncytial virus immune globulin, intravenous

# concept[].property[].valueString
No active NDCs or CPT codes associated to this CVX

# concept[].designation[].value
Venezuelan equine encephalitis, live, attenuated

# concept[].property[].valueString
This CVX code allows reporting of a vaccination when formulation is unknown (for example, when recording a adenovirus vaccination when noted on a vaccination card)

# concept[].designation[].value
hepatitis A vaccine, pediatric/adolescent dosage, 2 dose schedule

# concept[].designation[].value
hepatitis A vaccine, pediatric/adolescent dosage, 3 dose schedule

# concept[].property[].valueString
This vaccine formulation is inactive and should not be used, except to record historic vaccinations with this formulation.

# concept[].designation[].value
hepatitis A vaccine, unspecified formulation

# concept[].property[].valueString
This CVX code allows reporting of a vaccination when formulation is unknown (for example, when recording a HepA vaccination when noted on a vaccination card)

# concept[].designation[].value
influenza virus vaccine, unspecified formulation

# concept[].property[].valueString
This CVX code allows reporting of a vaccination when formulation is unknown (for example, when recording a Influenza vaccination when noted on a vaccination card)

# concept[].property[].valueString
This CVX code allows reporting of a vaccination when formulation is unknown (for example, when recording a polio vaccination when noted on a vaccination card)

# concept[].property[].valueString
This CVX code allows reporting of a vaccination when formulation is unknown (for example, when recording a rabies vaccination when noted on a vaccination card)

# concept[].property[].valueString
This CVX code allows reporting of a vaccination when formulation is unknown (for example, when recording a typhoid vaccination when noted on a vaccination card)

# concept[].property[].valueString
This CVX code allows reporting of a vaccination when formulation is unknown (for example, when recording a VEE vaccination when noted on a vaccination card)

# concept[].designation[].value
measles, mumps, rubella, and varicella virus vaccine

# concept[].designation[].value
tuberculin skin test; old tuberculin, multipuncture device

# concept[].designation[].value
tuberculin skin test; purified protein derivative solution, intradermal

# concept[].designation[].value
tuberculin skin test; purified protein derivative, multipuncture device

# concept[].designation[].value
tuberculin skin test; unspecified formulation

# concept[].property[].valueString
Code 99 will not be used in this table to avoid confusion with code 999.

# concept[].designation[].value
pneumococcal conjugate vaccine, 7 valent

# concept[].designation[].value
typhoid Vi capsular polysaccharide vaccine

# concept[].designation[].value
DTP- Haemophilus influenzae type b conjugate and hepatitis b vaccine

# concept[].property[].valueString
This CVX has been corrected. This non-US vaccine contained DTP, Hib and Hep B. It was withdrawn in 2007 .

# concept[].designation[].value
diphtheria, tetanus toxoids and acellular pertussis vaccine, 5 pertussis antigens

# concept[].designation[].value
diphtheria, tetanus toxoids and acellular pertussis vaccine, unspecified formulation

# concept[].property[].valueString
This CVX code allows reporting of a vaccination when formulation is unknown (for example, when recording a DTaP vaccination when noted on a vaccination card)

# concept[].property[].valueString
This CVX is intended for use when one of the meningococcal vaccines containing serogroups A, C, W and Y (conjugate or polysaccaride) was given and the exact formulation was not recorded. It should not be used to record newly administered immunizations. It is not to be used when one of the meningococcal vaccines containing other serogroups was administered.

# concept[].property[].valueString
This CVX code allows reporting of a vaccination when formulation is unknown (for example, when recording a pneumococcal vaccination when noted on a vaccination card)

# concept[].display
Influenza, live, trivalent, intranasal, PF

# concept[].designation[].value
Influenza, live, trivalent, intranasal, preservative free

# concept[].property[].valueString
HCP administered, trivalent code reactivated for 2024/2025 season

# concept[].display
Td (adult), 5 Lf tetanus toxoid, preservative free, adsorbed

# concept[].designation[].value
tetanus and diphtheria toxoids, adsorbed, preservative free, for adult use (5 Lf of tetanus toxoid and 2 Lf of diphtheria toxoid)

# concept[].designation[].value
meningococcal polysaccharide (groups A, C, Y and W-135) diphtheria toxoid conjugate vaccine (MCV4P)

# concept[].designation[].value
tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine, adsorbed

# concept[].designation[].value
varicella zoster immune globulin (Investigational New Drug)

# concept[].designation[].value
diphtheria, tetanus toxoids and acellular pertussis vaccine, Haemophilus influenzae type b conjugate, and poliovirus vaccine, inactivated (DTaP-Hib-IPV)

# concept[].property[].valueString
Zostavax vaccine associated to this CVX Code retired 10/2022

# concept[].designation[].value
influenza virus vaccine, H5N1, A/Vietnam/1203/2004 (national stockpile)

# concept[].designation[].value
Novel Influenza-H1N1-09, live virus for nasal administration

# concept[].property[].valueString
This code is used whenever the actual formulation is not determined or when aggregating all Novel H1N1 Influenza-09 immunizations for reporting to CRA. It should not be used for seasonal influenza vaccine that is not otherwise specified. (NOS)

# concept[].property[].valueString
This CVX code allows reporting of a vaccination when formulation is unknown (for example, when recording a JE vaccination when noted on a vaccination card)

# concept[].designation[].value
Diphtheria, tetanus toxoids and acellular pertussis vaccine, and poliovirus vaccine, inactivated

# concept[].designation[].value
Historical record of a typhus vaccination

# concept[].designation[].value
Historical diphtheria and tetanus toxoids and acellular pertussis, poliovirus, Haemophilus b conjugate and hepatitis B (recombinant) vaccine.

# concept[].property[].valueString
This is not the same as CVX 146, Hexavalent vaccine.

# concept[].designation[].value
pneumococcal conjugate vaccine, 13 valent

# concept[].designation[].value
Influenza, high-dose, split virus, trivalent, injectable, preservative free

# concept[].property[].valueString
Trivalent code reactivated for 2024/2025 season

# concept[].designation[].value
meningococcal oligosaccharide (groups A, C, Y and W-135) diphtheria toxoid conjugate vaccine (MCV4O)

# concept[].property[].valueString
This CVX code allows reporting of a vaccination when formulation is unknown (for example, when recording a HPV vaccination when noted on a vaccination card)

# concept[].designation[].value
tetanus and diphtheria toxoids, not adsorbed, for adult use

# concept[].property[].valueString
This CVX code allows reporting of a historic vaccination when the formulation is unknown (for example, when recording a Td vaccination when noted on a vaccination card)

# concept[].designation[].value
Influenza, split virus, trivalent, injectable, preservative free

# concept[].property[].valueString
Trivalent code reactivated for 2024/2025 season

# concept[].display
Influenza, split virus, trivalent, preservative

# concept[].designation[].value
Influenza, split virus, trivalent, injectable, contains preservative

# concept[].property[].valueString
Trivalent code reactivated for 2024/2025 season

# concept[].designation[].value
Adenovirus, type 4 and type 7, live, oral

# concept[].property[].valueString
This vaccine is administered as 2 tablets.

# concept[].property[].valueString
IIV3. No US product available since 2014/2015 flu season

# concept[].designation[].value
Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate (Meningococcal Protein Conjugate), and Hepatitis B (Recombinant) Vaccine.

# concept[].property[].valueString
This vaccine is different from CVX 132. Code may be used to document non-US vaccines (e.g. Hexamin) of the same component formulation

# concept[].designation[].value
Meningococcal, MCV4, unspecified conjugate formulation(groups A, C, Y and W-135)

# concept[].property[].valueString
This CVX should only be used for historical doses of meningococcal conjugate vaccine where the formulation is unknown (oligosaccharide vs polysaccharide). It is not the same as CVX 108, Meningococcal, unspecified formulation. This CVX is for unspecified Meningococcal conjugate vaccines.

# concept[].designation[].value
Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid Conjugate Vaccine

# concept[].property[].valueString
Quadrivalent code starting 2013/2014 season

# concept[].display
Influenza, split virus, quadrivalent, PF

# concept[].designation[].value
Influenza, split virus, quadrivalent, injectable, preservative free

# concept[].property[].valueString
Quadrivalent code starting 2013/2014 season

# concept[].property[].valueString
This CVX should only be used for historical records where the formulation of nasal flu vaccine is not known.

# concept[].property[].valueString
This CVX should only be used for historical records where the formulation of pneumococcal conjugate vaccine is not known.

# concept[].designation[].value
Influenza, Madin Darby Canine Kidney, subunit, trivalent, injectable, preservative free

# concept[].property[].valueString
Trivalent code reactivated for 2024/2025 season

# concept[].property[].valueString
Do not use this code. This product may be used for Hep A and other viral infections. The correct vaccine / CVX is 86 (IG).

# concept[].property[].valueString
Trivalent code reactivated for 2024/2025 season

# concept[].property[].valueString
This immune globulin may be administered either IM or IV.

# concept[].property[].valueString
This immune globulin may be administered IM only.

# concept[].designation[].value
Influenza, split virus, quadrivalent, injectable, contains preservative

# concept[].property[].valueString
Quadrivalent code starting 2013/2014 season

# concept[].display
Influenza A monovalent (H5N1), ADJUVANTED-2013

# concept[].designation[].value
Influenza A monovalent (H5N1), adjuvanted, National stockpile 2013

# concept[].property[].valueString
Approved by FDA 2013, adjuvant is mixed at point of administration.

# concept[].designation[].value
meningococcal B vaccine, fully recombinant

# concept[].designation[].value
meningococcal B vaccine, recombinant, OMV, adjuvanted

# concept[].property[].valueString
No US product available since 2017/2018 flu season

# concept[].designation[].value
meningococcal vaccine of unknown formulation and unknown serogroups

# concept[].property[].valueString
This CVX is intended for use when any one of the meningococcal vaccines is recorded and there is no information about which serogroups are protected against. This code should not be used when a newly administered immunization is recorded.

# concept[].property[].valueString
Trivalent code reactivated for 2024/2025 season

# concept[].property[].valueString
This vaccine is not available in the US.

# concept[].designation[].value
non-US diphtheria, tetanus toxoids and acellular pertussis vaccine, Haemophilus influenzae type b conjugate, and poliovirus vaccine, inactivated (DTaP-Hib-IPV)

# concept[].property[].valueString
This CVX was split off from CVX 102, to correctly identify the contents of the vaccine.

# concept[].designation[].value
Influenza, Madin Darby Canine Kidney, subunit, quadrivalent, injectable, preservative free

# concept[].property[].valueString
Quadrivalent code starting 2016/2017 season

# concept[].designation[].value
Human Rabies vaccine from human diploid cell culture

# concept[].designation[].value
Human rabies vaccine from Chicken fibroblast culture

# concept[].designation[].value
pneumococcal conjugate vaccine, 10 valent

# concept[].designation[].value
Non-US bivalent oral polio vaccine (types 1 and 3)

# concept[].property[].valueString
This is a non-US vaccine that may be seen in some immunization histories.

# concept[].designation[].value
Non-US monovalent oral polio vaccine, unspecified formulation

# concept[].property[].valueString
This is a non-US vaccine that may be seen in some immunization histories. It is composed of either Type 1, Type 2 or Type 3 oral polio vaccine.

# concept[].property[].valueString
This record duplicates CVX 13 (TIG). Do not use CVX 180.

# concept[].designation[].value
Oral Polio Vaccine, Unspecified formulation

# concept[].property[].valueString
This code represents an oral polio vaccine where the specific formulation is unknown.

# concept[].designation[].value
Yellow fever vaccine live - alternative formulation for vaccine shortage

# concept[].property[].valueString
This CVX is associated to an FDA unapproved drug to be used when there is a drug shortage. Stabilized with sorbitol and lactose and has been used outside the US for some time.

# concept[].designation[].value
Yellow fever vaccine, unspecified formulation

# concept[].property[].valueString
Quadrivalent code starting 2017/2018 season

# concept[].designation[].value
Influenza, Madin Darby Canine Kidney, subunit, quadrivalent, injectable, contains preservative

# concept[].property[].valueString
Quadrivalent code starting 2017/2018 season

# concept[].property[].valueString
This CVX code allows reporting of a vaccination when formulation is unknown (for example, when recording a zoster vaccination when noted on a vaccination card)

# concept[].designation[].value
Hepatitis B vaccine (recombinant), CpG adjuvanted

# concept[].designation[].value
meningococcal A polysaccharide vaccine (non-US)

# concept[].designation[].value
meningococcal AC polysaccharide vaccine (non-US)

# concept[].designation[].value
hepatitis A and hepatitis B vaccine, pediatric/adolescent (non-US)

# concept[].property[].valueString
This CVX code should be used to record administration of Southern Hemisphere influenza vaccine where formulation is unknown

# concept[].property[].valueString
This code should be used to document non-US vaccines for DT,IPV such as Revaxis

# concept[].display
Td, adsorbed, preservative free, adult use, Lf unspecified

# concept[].designation[].value
tetanus and diphtheria toxoids, adsorbed, preservative free, for adult use, Lf unspecified

# concept[].property[].valueString
Used when Td Lf specification is unknown

# concept[].designation[].value
Influenza, high-dose, split virus, quadrivalent, injectable, preservative free

# concept[].property[].valueString
Quadrivalent code starting season 2020/2021

# concept[].designation[].value
Diphtheria, pertussis, tetanus, hepatitis B, Haemophilus Influenza Type b, (Pentavalent)

# concept[].property[].valueString
This represents the non-US pentavalent vaccine.  Should be used for historic documentation in US

# concept[].display
influenza, Southern Hemisphere, pediatric, preservative free

# concept[].designation[].value
influenza, seasonal, Southern Hemisphere, quadrivalent, pediatric 0.25mL dose, preservative free

# concept[].display
Influenza, Southern Hemisphere, quadrivalent, PF

# concept[].designation[].value
Influenza, seasonal, Southern Hemisphere, quadrivalent, 0.5 mL dose, preservative free

# concept[].designation[].value
influenza, seasonal, Southern Hemisphere, quadrivalent, 0.5mL dose, with preservative

# concept[].designation[].value
meningococcal polysaccharide (groups A, C, Y, W-135) tetanus toxoid conjugate vaccine 0.5mL dose, preservative free

# concept[].display
Ebola Zaire vaccine, live, recombinant, 1mL dose

# concept[].designation[].value
Ebola Zaire vaccine, live, recombinant, 1mL dose

# concept[].property[].valueString
Quadrivalent code starting 2020/2021 season

# concept[].display
Vaccinia, smallpox Mpox vaccine live, PF, SQ or ID injection

# concept[].designation[].value
Vaccinia, smallpox monkeypox vaccine, live attenuated, preservative free, subcutaneous or intradermal injection

# concept[].property[].valueString
Associated to FDA US Licensed product JYNNEOS, non-US tradenames IMVANEX, IMVAMUNE. Review CDC & FDA guidance for updates regarding administration

# concept[].display
COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose

# concept[].designation[].value
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose

# concept[].property[].valueString
Original monovalent Moderna adult vaccine. FDA rescinded all doses for US use 4/18/2023. Continue to used to record historic US Moderna vaccines and those administered in non-US locations (includes tradename Spikevax)

# concept[].display
COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose

# concept[].designation[].value
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3mL dose

# concept[].property[].valueString
Original monovalent Pfizer adult vaccine (12+ yrs). FDA rescinded all doses for US use 4/18/2023.  Continue to use to record historic US Pfizer vaccines and Non-US vaccines administered (includes tradename Comirnaty)

# concept[].display
COVID-19 vaccine, vector-nr, rS-ChAdOx1, PF, 0.5 mL

# concept[].designation[].value
SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-ChAdOx1, preservative free, 0.5 mL

# concept[].property[].valueString
WHO authorized pandemic vaccine.  Recognized towards immunity in US.  AstraZeneca vaccine non-US WHO authorized tradenames/identifiers include VAXZEVRIA, AZD1222, ChAdOx1 nCoV-19, COVISHIELD

# concept[].display
COVID-19, subunit, rS-nanoparticle+Matrix-M1 Adjuvant, PF, 0.5 mL

# concept[].designation[].value
SARS-COV-2 (COVID-19) vaccine, subunit, recombinant spike protein-nanoparticle+Matrix-M1 Adjuvant, preservative free, 0.5mL dose

# concept[].property[].valueString
Original monovalent Novavax vaccine (12+ years), FDA rescinded for US doses 10/03/2023. Continue to use to record Novavax Non-US vaccines administered (includes tradenames NUVAXOVID, COVOVAX)

# concept[].display
COVID-19 vaccine, vector-nr, rS-Ad26, PF, 0.5 mL

# concept[].designation[].value
SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL

# concept[].property[].valueString
Original monovalent Janssen/J&J adult vaccine. All NDCs expired 6/20/2023, not reauthorized by FDA for Fall 2023 US doses. Continue to use to record Jansses/J&J Non-US vaccines administered vaccines administered

# concept[].property[].valueString
Unspecified code for COVID-19 not to be used to record patient US administration. May be used to record historic US administration if product not known.  CVX code 500 should be used to record Non-US vaccine where product is not known.

# concept[].display
Pneumococcal conjugate PCV15, polysaccharide CRM197 conjugate, adjuvant, PF

# concept[].designation[].value
Pneumococcal conjugate vaccine 15-valent (PCV15), polysaccharide CRM197 conjugate, adjuvant, preservative free

# concept[].display
Pneumococcal conjugate PCV20, polysaccharide CRM197 conjugate, adjuvant, PF

# concept[].designation[].value
Pneumococcal conjugate vaccine 20-valent (PCV20), polysaccharide CRM197 conjugate, adjuvant, preservative free

# concept[].display
COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose, tris-sucrose

# concept[].designation[].value
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3mL dose, tris-sucrose formulation

# concept[].property[].valueString
Original monovalent Pfizer tris-sucrose formulation FDA EUA (12+ yrs) and BLA (16+ yrs), FDA rescinded monovalent use 08/31/2022, BLA NDCs not retired until 09/11/2023.

# concept[].display
COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose

# concept[].designation[].value
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 10 mcg/0.2mL dose, tris-sucrose formulation

# concept[].property[].valueString
Original monovalent Pfizer tris-sucrose formulation (5 yrs through 11 yrs), FDA rescinded 4/18/2023

# concept[].display
COVID-19, mRNA, LNP-S, PF, 3 mcg/0.2 mL dose, tris-sucrose

# concept[].designation[].value
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 3 mcg/0.2mL dose, tris-sucrose formulation

# concept[].property[].valueString
Original monovalent Pfizer tris-sucrose formulation (6 mo through 4 yrs), FDA rescinded 4/18/2023

# concept[].designation[].value
Hepatitis B vaccine (recombinant), 3-antigen, Al(OH)3 adjuvanted

# concept[].property[].valueString
Manufacturer VBI has ceased operations - Prehevbrio Hep B vaccine voluntary recall effective 11/15/2024

# concept[].display
COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL dose

# concept[].designation[].value
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 50 mcg/0.5 mL dose

# concept[].property[].valueString
Original monovalent Moderna, (Adult) FDA rescinded 4/18/2023, (6 yrs through 11 yrs) FDA rescinded 04/18/2023

# concept[].property[].valueString
Unspecified Code - should only be used when specific vaccine administered is unknown

# concept[].display
Tick-borne encephalitis, inactivated, PF, 0.25mL

# concept[].designation[].value
Tick-borne encephalitis vaccine, inactivated, preservative free, 0.25mL dose

# concept[].display
Tick-borne encephalitis, inactivated, PF, 0.5mL

# concept[].designation[].value
Tick-borne encephalitis vaccine, inactivated, preservative free, 0.5mL dose

# concept[].display
COVID-19, D614, recomb, preS dTM, AS03 adjuvant add, PF, 5mcg/0.5mL

# concept[].designation[].value
SARS-COV-2 (COVID-19) vaccine, D614, prefusion spike recombinant protein subunit (CoV2 preS dTM), AS03 adjuvant added, preservative free, 5mcg/0.5mL dose

# concept[].display
COVID-19, D614, recomb, preS dTM, AS03 adjuvant add, PF, 10mcg/0.5mL

# concept[].designation[].value
SARS-COV-2 (COVID-19) vaccine, D614, prefusion spike recombinant protein subunit (CoV2 preS dTM), AS03 adjuvant added, preservative free, 10mcg/0.5mL dose

# concept[].display
COVID-19, mRNA, LNP-S, PF, pediatric 50 mcg/0.5 mL dose

# concept[].designation[].value
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, pediatric 50 mcg/0.5 mL dose

# concept[].property[].valueString
Original monovalent Moderna pediatric vaccine (FDA rescinded 4/18/2023). Inactivated 6/14/2022 to use CVX code 221 product instead

# concept[].display
COVID-19, mRNA, LNP-S, PF, pediatric 25 mcg/0.25 mL dose

# concept[].designation[].value
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, pediatric 25 mcg/0.25 mL dose

# concept[].property[].valueString
Original monovalent Moderna pediatric vaccine (6 mo through 5 yrs), FDA rescinded 4/18/2023

# concept[].display
COVID-19, mRNA, LNP-S, bivalent, PF, 50 mcg/0.5 mL or 25mcg/0.25 mL dose

# concept[].designation[].value
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent, preservative free, 50 mcg/0.5 mL or 25 mcg/0.25 mL dose

# concept[].property[].valueString
Original strain + omicron BA.4/BA.5 bivalent Moderna vaccine (6 mo and older), FDA rescinded 9/11/2023.  Continue to use to record Non-US vaccines administered (tradename Spikevax Bivalent)

# concept[].display
COVID-19, mRNA, LNP-S, bivalent, PF, 10 mcg/0.2 mL

# concept[].designation[].value
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent, preservative free, 10 mcg/0.2 mL dose

# concept[].property[].valueString
Original strain + omicron BA.4/BA.5 bivalent Moderna vaccine (6 mo through 5 yrs), FDA rescinded 9/11/2023

# concept[].designation[].value
influenza, seasonal, Southern Hemisphere, high-dose, quadrivalent, 0.7mL dose, preservative free

# concept[].property[].valueString
Target population 65 and older, starting Southern Hemisphere season 2023

# concept[].display
COVID-19, mRNA, LNP-S, bivalent, PF, 30 mcg/0.3 mL dose

# concept[].designation[].value
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent, preservative free, 30 mcg/0.3 mL dose, tris-sucrose formulation

# concept[].property[].valueString
Original strain + omicron BA.4/BA.5 bivalent Pfizer vaccine (12 yrs and older). FDA rescinded 09/11/2023.  Continue to use to record Non-US vaccines administered (tradename Comirnaty Bivalent)

# concept[].display
COVID-19, mRNA, LNP-S, bivalent, PF, 10 mcg/0.2 mL dose

# concept[].designation[].value
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent, preservative free, 10 mcg/0.2 mL dose, tris-sucrose formulation

# concept[].property[].valueString
Original strain + omicron BA.4/BA.5 bivalent Pfizer vaccine (5 yrs through 11 yrs), FDA rescinded 9/11/2023

# concept[].display
COVID-19, mRNA, LNP-S, bivalent, PF, 3 mcg/0.2 mL dose

# concept[].designation[].value
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent, preservative free, 3 mcg/0.2 mL dose, tris-sucrose formulation

# concept[].property[].valueString
Original strain + omicron BA.4/BA.5 bivalent Pfizer vaccine (6 mo through 4 yrs), FDA rescinded 09/11/2023

# concept[].display
RSV, recombinant, protein subunit RSVpreF, adjuvant reconstituted, 0.5 mL, PF

# concept[].designation[].value
Respiratory syncytial virus (RSV), vaccine, recombinant, protein subunit RSV prefusion F, adjuvant reconstituted, 0.5 mL, preservative free

# concept[].display
Respiratory syncytial virus (RSV), unspecified

# concept[].designation[].value
Respiratory syncytial virus (RSV), unspecified

# concept[].property[].valueString
Unspecified, for historic records where it is not known if RSV vaccine or RSV MAB was administered

# concept[].display
RSV, bivalent, protein subunit RSVpreF, diluent reconstituted, 0.5 mL, PF

# concept[].designation[].value
Respiratory syncytial virus (RSV), vaccine, bivalent, protein subunit RSV prefusion F, diluent reconstituted, 0.5 mL, preservative free

# concept[].property[].valueString
Adults 60 years and older, pregnant individuals

# concept[].display
RSV, mAb, nirsevimab-alip, 0.5 mL, neonate to 24 months

# concept[].designation[].value
Respiratory syncytial virus (RSV) monoclonal antibody, IgG1κ , (nirsevimab-alip), 0.5 mL, neonates and children to 24 months

# concept[].display
RSV, mAb, nirsevimab-alip, 1 mL, neonate to 24 months

# concept[].designation[].value
Respiratory syncytial virus (RSV) monoclonal antibody, IgG1κ , (nirsevimab-alip), 1 mL, neonates and children to 24 months

# concept[].display
COVID-19, mRNA, LNP-S, PF, tris-sucrose, 3 mcg/0.3 mL

# concept[].designation[].value
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, tris-sucrose, 3 mcg/0.3 mL dose

# concept[].property[].valueString
Pfizer Fall Seasonal 6 months through 4 years of age

# concept[].display
COVID-19, mRNA, LNP-S, PF, tris-sucrose, 30 mcg/0.3 mL

# concept[].designation[].value
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, tris-sucrose, 30 mcg/0.3 mL dose

# concept[].display
COVID-19, mRNA, LNP-S, PF, tris-sucrose, 10 mcg/0.3 mL

# concept[].designation[].value
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, tris-sucrose, 10 mcg/0.3 mL dose

# concept[].property[].valueString
Pfizer Fall Seasonal 5 years through 11 years of age

# concept[].designation[].value
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 25 mcg/0.25 mL dose

# concept[].property[].valueString
Moderna Fall Seasonal 6 months through 11 years of age

# concept[].designation[].value
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 50 mcg/0.5 mL dose

# concept[].property[].valueString
Moderna Fall Seasonal 12 years and older

# concept[].display
COVID-19, subunit, rS-nanoparticle, adjuvanted, PF, 5 mcg/0.5 mL

# concept[].designation[].value
SARS-COV-2 (COVID-19) vaccine, subunit, recombinant spike protein-nanoparticle+Matrix-M1 Adjuvant, preservative free, 5 mcg/0.5 mL dose

# concept[].property[].valueString
Novavax Fall Seasonal 12 years and older

# concept[].display
Respiratory syncytial virus (RSV) vaccine, unspecified

# concept[].designation[].value
Respiratory syncytial virus (RSV) vaccine, unspecified

# concept[].property[].valueString
Unspecified, for historic records where the specific vaccine administered is not known

# concept[].display
Respiratory syncytial virus (RSV) MAB, unspecified

# concept[].designation[].value
Respiratory syncytial virus (RSV) monoclonal antibody (MAB), unspecified

# concept[].property[].valueString
Unspecified, for historic records where the specific RSV MAB administered is not known

# concept[].designation[].value
Meningococcal polysaccharide (groups A, C, Y, W) tetanus toxoid conjugate, meningococcal B recombinant vaccine, 0.5mL, preservative free

# concept[].property[].valueString
Meningococcal pentavalent vaccine strains ABCW and Y

# concept[].display
Chikungunya live attenuated vaccine, 0.5 mL, PF

# concept[].designation[].value
Chikungunya, live attenuated vaccine, 0.5 mL, preservative free

# concept[].property[].valueString
Unspecified code to record historic administration when specific product is unknown

# concept[].designation[].value
Influenza, Madin Darby Canine Kidney, subunit, trivalent, injectable, contains preservative

# concept[].property[].valueString
Trivalent code starting 2024/2025 season

# concept[].property[].valueString
Unspecified code H5xx vaccines to be used when specific formulation is unknown - for vaccines administered starting 2024

# concept[].property[].valueString
Non-US polio vaccine administered since 2016

# concept[].property[].valueString
Use this CVX for historical records where; the formulation administered is not known, or is a non-US product without an associated CVX code.

# concept[].designation[].value
Respiratory syncytial virus (RSV), mRNA, injectable, preservative free

# concept[].display
Pneumococcal conjugate PCV21, polysaccharide CRM197 conjugate, PF

# concept[].designation[].value
Pneumococcal conjugate vaccine, 21 valent (PCV21), polysaccharide CRM197 conjugate, preservative free

# concept[].designation[].value
Meningococcal oligosaccharide conjugated (groups A, C, W, Y) and group B, 0.5 mL, preservative free

# concept[].property[].valueString
Meningococcal pentavalent vaccine strains ABCW and Y

# concept[].display
Chikungunya, VLP, recombinant, 0.8 mL, PF

# concept[].designation[].value
Chikungunya, virus-like particle (VLP), recombinant vaccine, 0.8 mL, preservative free

# concept[].property[].valueString
Use this CVX for historical records where; the formulation of the dengue vaccine administered is not known, or is a non-US product without an associated CVX code.

# concept[].display
Influenza, Southern Hemisphere, trivalent, PF

# concept[].designation[].value
Influenza, seasonal, Southern Hemisphere, trivalent, 0.5 mL dose, preservative free

# concept[].display
RSV, mAb, clesrovimab-cfor, 0.7 mL, neonate and infant, PF

# concept[].designation[].value
Respiratory syncytial virus (RSV), monoclonal antibody, IgG1κ , (clesrovimab-cfor), 0.7 mL, neonate and infant, preservative free

# concept[].property[].valueString
RSV mAb for neonates and infants born during or entering first RSV season (Enflonsia)

# concept[].display
Influenza, live, trivalent, intranasal, self/caregiver admin, PF

# concept[].designation[].value
Influenza, live, trivalent, intranasal, self or caregiver administered, preservative free

# concept[].property[].valueString
Self or caregiver administered, new starting 2025/2026 season

# concept[].display
COVID-19 Non-US Vaccine, Product Unknown

# concept[].designation[].value
SARS-COV-2 COVID-19 Non-US Vaccine, Specific Product Unknown

# concept[].property[].valueString
Pandemic Non-US Covid Administration - specific CVX or product unknown

# concept[].display
COVID-19 IV Non-US Vaccine (QAZCOVID-IN)

# concept[].designation[].value
SARS-COV-2 COVID-19 Inactivated Virus Non-US Vaccine Product (QAZCOVID-IN)

# concept[].property[].valueString
Pandemic Non-US Vaccine not Authorized by WHO - not counted toward  immunity in US

# concept[].designation[].value
SARS-COV-2 COVID-19 Inactivated Virus Non-US Vaccine Product (COVAXIN)

# concept[].designation[].value
SARS-COV-2 COVID-19 Live Attenuated Virus Non-US Vaccine Product (COVIVAC)

# concept[].property[].valueString
Pandemic Non-US Vaccine not Authorized by WHO - not counted toward  immunity in US

# concept[].display
COVID-19 VVnr Non-US Vaccine (Sputnik Light)

# concept[].designation[].value
SARS-COV-2 COVID-19 Viral Vector Non-replicating Non-US Vaccine Product (Sputnik Light)

# concept[].property[].valueString
Pandemic Non-US Vaccine not Authorized by WHO - not counted toward  immunity in US

# concept[].display
COVID-19 VVnr Non-US Vaccine (Sputnik V)

# concept[].designation[].value
SARS-COV-2 COVID-19 Viral Vector Non-replicating Non-US Vaccine Product (Sputnik V)

# concept[].property[].valueString
Pandemic Non-US Vaccine not Authorized by WHO - not counted toward  immunity in US

# concept[].display
COVID-19 VVnr Non-US Vaccine (CanSino Biological Inc./Beijing Institute of Biotechnology

# concept[].designation[].value
SARS-COV-2 COVID-19 Viral Vector Non-replicating Non-US Vaccine Product (CONVIDECIA), CanSino Biological Inc./Beijing Institute of Biotechnology

# concept[].property[].valueString
Pandemic Non-US Vaccine. Authorized by WHO 5/19/2022 - Counted toward immunity in US

# concept[].display
COVID-19 PS Non-US Vaccine (Anhui Zhifei Longcom Biopharm + Inst of Micro, Chinese Acad of Sciences)

# concept[].designation[].value
SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (Anhui Zhifei Longcom Biopharmaceutical + Institute of Microbiology, Chinese Academy of Sciences)

# concept[].property[].valueString
Pandemic Non-US Vaccine not Authorized by WHO - not counted toward immunity in US

# concept[].display
COVID-19 PS Non-US Vaccine (Jiangsu Province Centers for Disease Control and Prevention)

# concept[].designation[].value
SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (Jiangsu Province Centers for Disease Control and Prevention)

# concept[].property[].valueString
Pandemic Non-US Vaccine not Authorized by WHO - not counted toward  immunity in US

# concept[].display
COVID-19 PS Non-US Vaccine (EpiVacCorona)

# concept[].designation[].value
SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (EpiVacCorona)

# concept[].property[].valueString
Pandemic Non-US Vaccine not Authorized by WHO - not counted toward  immunity in US

# concept[].display
COVID-19 IV Non-US Vaccine (BIBP, Sinopharm)

# concept[].designation[].value
SARS-COV-2 COVID-19 Inactivated Virus Non-US Vaccine Product (BIBP, Sinopharm)

# concept[].property[].valueString
Pandemic Non-US Vaccine. Authorized by WHO - Counted toward immunity in US

# concept[].display
COVID-19 IV Non-US Vaccine (CoronaVac, Sinovac)

# concept[].designation[].value
SARS-COV-2 COVID-19 Inactivated Virus Non-US Vaccine Product (CoronaVac, Sinovac)

# concept[].property[].valueString
Pandemic Non-US Vaccine. Authorized by WHO - Counted toward immunity in US

# concept[].display
SARS-COV-2 COVID-19 VLP Non-US Vaccine (Medicago, Covifenz)

# concept[].designation[].value
SARS-COV-2 COVID-19 Virus Like Particle (VLP) Non-US Vaccine Product (Medicago, Covifenz)

# concept[].property[].valueString
Pandemic Non-US Vaccine not Authorized by WHO - ACIP does recognize towards immunity in US

# concept[].display
SARS-COV-2 COVID-19 PS Non-US Vaccine (Anhui Zhifei Longcom, Zifivax)

# concept[].designation[].value
SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (Anhui Zhifei Longcom, Zifivax)

# concept[].property[].valueString
Pandemic Non-US Vaccine not Authorized by WHO - not counted toward immunity in US

# concept[].display
SARS-COV-2 COVID-19 DNA Non-US Vaccine (Zydus Cadila, ZyCoV-D)

# concept[].designation[].value
SARS-COV-2 COVID-19 DNA Non-US Vaccine Product (Zydus Cadila, ZyCoV-D)

# concept[].property[].valueString
Pandemic Non-US Vaccine not Authorized by WHO - not counted toward immunity in US

# concept[].display
SARS-COV-2 COVID-19 PS Non-US Vaccine (Medigen, MVC-COV1901)

# concept[].designation[].value
SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (Medigen, MVC-COV1901)

# concept[].property[].valueString
Pandemic Non-US Vaccine not Authorized by WHO - not counted toward immunity in US

# concept[].display
COV-2 COVID-19 Inactivated Non-US Vaccine Product (Minhai Biotechnology Co, KCONVAC)

# concept[].designation[].value
SARS-COV-2 COVID-19 Inactivated Non-US Vaccine Product (Minhai Biotechnology Co, KCONVAC)

# concept[].property[].valueString
Pandemic Non-US Vaccine not Authorized by WHO - not counted toward immunity in US

# concept[].display
SARS-COV-2 COVID-19 PS Non-US Vaccine (Biological E Limited, Corbevax)

# concept[].designation[].value
SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (Biological E Limited, Corbevax)

# concept[].property[].valueString
Pandemic Non-US Vaccine not Authorized by WHO - not counted toward immunity in US

# concept[].display
COVID-19 Inactivated, Non-US Vaccine (VLA2001, Valneva)

# concept[].designation[].value
SARS-COV-2 COVID-19 Inactivated, Non-US Vaccine (VLA2001, Valneva)

# concept[].property[].valueString
Pandemic Non-US Vaccine not Authorized by WHO - not counted toward immunity in US

# concept[].display
COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine (Spikevax Bivalent), Moderna

# concept[].designation[].value
SARS-COV-2 COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine (Spikevax Bivalent), Moderna

# concept[].property[].valueString
Pandemic Non-US Vaccine not Authorized by WHO - Is authorized by EU and counted toward immunity in US

# concept[].display
COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine Product, Pfizer-BioNTech

# concept[].designation[].value
SARS-COV-2 COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine Product (Comirnaty Bivalent), Pfizer-BioNTech

# concept[].property[].valueString
Pandemic Non-US Vaccine. Authorized by WHO 10/19/2022 - Counted toward immunity in US

# concept[].display
COVID-19 SP, protein-based, adjuvanted (VidPrevtyn Beta), Sanofi-GSK

# concept[].designation[].value
SARS-COV-2 (COVID-19) vaccine SP, protein-based, adjuvanted, B.1.351 strain (VidPrevtyn Beta), Sanofi-GSK

# concept[].property[].valueString
Pandemic Non-US Vaccine not Authorized by WHO - not counted toward immunity in US

# concept[].property[].valueString
This is the adjuvant that is packaged with H5N1 vaccine, adjuvanted

# concept[].property[].valueString
Code 998 was added for use in VXU HL7 messages where the OBX segment is nested with the RXA segment, but the message does not contain information about a vaccine administration. An example of this use is to report the vaccines due next for a patient when no vaccine administration is being reported.

# concept[].property[].valueString
This CVX code has little utility and should rarely be used.